Amylyx Pharmaceuticals (AMLX) News Today $3.34 -0.20 (-5.65%) Closing price 04:00 PM EasternExtended Trading$3.32 -0.02 (-0.75%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, three have issuedMarch 31 at 2:19 AM | marketbeat.comIs Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $37,000.00 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director Bernhardt G. Zeiher purchased 10,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $37,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.March 25, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires $37,000.00 in StockMarch 25, 2025 | insidertrades.comKennondale Capital Management LLC Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Kennondale Capital Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 134,445 shares of the company's stock, valuedMarch 19, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 43.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,263,353 shares of the company's stocMarch 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for AMLX FY2025 Earnings?Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst A. Fein now expects tMarch 10, 2025 | marketbeat.comAnalysts Offer Predictions for AMLX Q1 EarningsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a research report issued on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.43) per share for the quMarch 8, 2025 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday.March 6, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, three have issued a buy recommendation aMarch 6, 2025 | marketbeat.comAmylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 5, 2025 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comAmylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO DiscontinuationMarch 5, 2025 | tipranks.comAmylyx Pharmaceuticals Reports 2024 Financial ResultsMarch 4, 2025 | tipranks.comAmylyx Pharmaceuticals’ Earnings Call Highlights Clinical ProgressMarch 4, 2025 | tipranks.comAmylyx reports Q4 EPS (55c) vs. 7c last yearMarch 4, 2025 | markets.businessinsider.comAmylyx files $300M mixed securities shelfMarch 4, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest UpdateAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 3,380,000 shares, a growth of 30.5% from the January 31st total of 2,590,000 shares. Currently, 6.8% of the company's shares are sold short. Based on an average trading volume of 820,300 shares, the days-to-cover ratio is currently 4.1 days.March 4, 2025 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Announces Earnings ResultsAmylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06).March 4, 2025 | marketbeat.comAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | businesswire.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $13,132.35 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 4,169 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $3.15, for a total value of $13,132.35. Following the completion of the sale, the insider now owns 134,921 shares of the company's stock, valued at approximately $425,001.15. This trade represents a 3.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.February 27, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 4,169 SharesFebruary 27, 2025 | insidertrades.comAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | finance.yahoo.comAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesFebruary 25, 2025 | businesswire.comAmylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of RecoveryFebruary 24, 2025 | seekingalpha.comAmylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, February 27.February 20, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Position Lowered by abrdn plcabrdn plc lowered its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 12.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,722,805 shares of the company's stock after seFebruary 9, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, three have issuedFebruary 9, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $12,836.22 in StockFebruary 6, 2025 | insidertrades.comAmylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in sharesFebruary 5, 2025 | msn.comInsider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 3,678 Shares of StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.49, for a total value of $12,836.22. Following the sale, the insider now owns 139,090 shares in the company, valued at $485,424.10. This represents a 2.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.February 5, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $41,122.97 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Joshua B. Cohen sold 11,851 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares of the company's stock, valued at $11,108,327.09. The trade was a 0.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.February 5, 2025 | marketbeat.comFY2025 Earnings Forecast for AMLX Issued By Leerink PartnrsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.35)January 31, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. Common Stock (AMLX) Institutional HoldingsJanuary 31, 2025 | nasdaq.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Increase in Short InterestAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,940,000 shares, a growth of 23.6% from the December 31st total of 1,570,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 4.5% of the shares of the stock are short sold.January 30, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)JPMorgan Chase & Co. grew its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 144.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,559 shares of the company's stock after buyingJanuary 29, 2025 | marketbeat.comAmylyx Says FDA Lifts Clinical Hold on ALS-Drug TrialJanuary 21, 2025 | marketwatch.comFDA clears Amylyx to resume ALS drug trial in North AmericaJanuary 21, 2025 | msn.comFDA lifts clinical hold on Amylyx ALS drug studyJanuary 21, 2025 | msn.comAmylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral SclerosisJanuary 21, 2025 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, three have assigned aJanuary 15, 2025 | marketbeat.comAmylyx announces common stock offering, no amount givenJanuary 10, 2025 | markets.businessinsider.comAmylyx stock dips after pricing $60M stock offeringJanuary 10, 2025 | seekingalpha.comAmylyx Pharmaceuticals Prices Offering Of Approx. 17.1 Mln Shares At $3.50 Per ShareJanuary 10, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockJanuary 10, 2025 | businesswire.comAmylyx Pharma Commences Underwritten Public Offering Of SharesJanuary 10, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals Announces Proposed Public Offering of Common StockJanuary 9, 2025 | businesswire.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin B. Klee Sells 7,471 SharesJanuary 9, 2025 | insidertrades.comJustin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the transaction, the chief executive officer now owns 3,176,788 shares of the company's stock, valued at $12,834,223.52. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 8, 2025 | marketbeat.comAmylyx appoints Dan Monahan as Chief Commercial OfficerJanuary 6, 2025 | markets.businessinsider.com Remove Ads Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Media Mentions By Week AMLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.830.78▲Average Medical News Sentiment AMLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼23▲AMLX Articles Average Week Remove Ads Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 89bio News Today Adaptive Biotechnologies News Today Evotec News Today ARS Pharmaceuticals News Today Ardelyx News Today Ocular Therapeutix News Today Structure Therapeutics News Today Calliditas Therapeutics AB (publ) News Today Iovance Biotherapeutics News Today Syndax Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts